Effects of oral zinc gluconate on glucose effectiveness and insulin sensitivity in humans. 1995

J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
Hôpital Lapeyronie, Montpellier, France.

Zinc improves both insulin secretion and insulin sensitivity, and exerts insulin-like effects. We investigated its acute effects on the parameters of glucose assimilation determined with the minimal model technique from frequent sampling intravenous glucose tolerance test (FSIVGTT) in seven healthy volunteers. FSIVGTTs (0.5 g/kg of glucose, followed by 2 U insulin i.v. injection at 19 min) were performed after the subjects had taken 20 mg zinc gluconate twice (the evening before and 30 min before the beginning of the test) or placebo pills (simple blind randomized protocol). Glucose assimilation was analyzed by calculating Kg (slope of the exponential decrease in glycemia), glucose effectiveness Sg (i.e., ability of glucose itself to increase its own disposal independent of insulin response), and SI (insulin sensitivity, i.e. the effect of increases in insulinemia on glucose disposal). The two latter parameters were calculated by fitting the experimental data with the two equations of Bergman's "minimal model." Zinc increased Kg (p < 0.05) and Sg (p < 0.05), whereas SI and insulin first-phase secretion did not significantly increase. This study suggests that zinc improves glucose assimilation, as evidenced by the increase in Kg, and that this improvement results mainly from an increase in glucose effectiveness (insulin-like effect), rather than an action on insulin response or insulin sensitivity.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005260 Female Females
D005942 Gluconates Derivatives of gluconic acid (the structural formula HOCH2(CHOH)4COOH), including its salts and esters. Copper Gluconate,Gluconate, Copper
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
April 2013, Diabetes care,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
May 2024, The Journal of clinical endocrinology and metabolism,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
December 1999, The American journal of physiology,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
April 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
June 1987, Agents and actions,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
November 1992, Diabetes care,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
April 2013, Obesity (Silver Spring, Md.),
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
January 1990, Biological trace element research,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
March 2019, Endocrine,
J F Brun, and R Guintrand-Hugret, and C Fons, and J Carvajal, and C Fedou, and M Fussellier, and L Bardet, and A Orsetti
January 2010, Annals of the Academy of Medicine, Singapore,
Copied contents to your clipboard!